Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
about
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor MilieuB7-H5 costimulates human T cells via CD28HA comprehensive overview of targeted therapy in metastatic renal cell carcinomaSafety, activity, and immune correlates of anti-PD-1 antibody in cancerRole of PD-1 in HIV pathogenesis and as target for therapyImmunobiology and immunotherapy in genitourinary malignanciesContemporary Treatment of Metastatic Renal Cell CarcinomaNew targeted treatments for non-small-cell lung cancer - role of nivolumabPD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?The role of pembrolizumab in the treatment of advanced non-small cell lung cancerEmerging molecular classifications and therapeutic implications for gastric cancerProfile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancerThe immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpointsLymphocyte-activation gene-3, an important immune checkpoint in cancerRole of the tumor microenvironment in mature B-cell lymphoid malignanciesImmunotherapy for cancer in the central nervous system: Current and future directionsClinical utility of nivolumab in the treatment of advanced melanomaAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraChimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsGenetics and biology of pancreatic ductal adenocarcinomaThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseAdvances in immunotherapy for melanomaPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesResults of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancerTargeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer TreatmentNovel technologies and emerging biomarkers for personalized cancer immunotherapyViro-immune therapy: A new strategy for treatment of pancreatic cancerImmune Checkpoint Modulation in Colorectal Cancer: What's New and What to ExpectImmune checkpoint inhibitors: therapeutic advances in melanomaTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaPromises and paradoxes of regulatory T cells in inflammatory bowel diseaseMolecular profiling in the treatment of colorectal cancer: focus on regorafenibPredictive factors for immunotherapy in melanomaAdvances in immunotherapy for treatment of lung cancerRelevance of tumor-infiltrating lymphocytes in breast cancerAntagonists of PD-1 and PD-L1 in Cancer TreatmentThe progress of immunotherapy for glioblastomaThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsNivolumab in the treatment of malignant melanoma: review of the literatureAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics
P2860
Q21131200-A8FB79EA-00D3-48DC-BD53-A3F0D8FA32F7Q24295841-3CC29CBE-F066-459E-95D1-CEEFF0B31F14Q24606852-0AC7E35A-E546-4A5F-BC90-210AC650E1E4Q24633070-5D78B785-F70A-4EC4-BE68-04A006C0470AQ24634293-5CF5DB0A-D657-4E1C-B67C-4C2B3EFA2908Q26738668-B2BE97E2-BDCE-41DF-A63B-654ACE800DB0Q26740594-4AB1DD57-8426-4B06-A012-63B7F2613EE7Q26740988-376A8319-6424-49CF-A41E-BA7BDE19F138Q26741101-4AA354D1-0CD7-432B-BAAC-3F5A83B25242Q26744076-73950C12-414A-427F-9637-AC6D3DF74787Q26745525-44BA7D91-26CD-4685-9FE2-0569A77CF443Q26745590-661EFD15-1B78-4497-B45C-C1169790DF6AQ26745842-2794B1FE-34B6-4F02-9A18-C1C7DD4A0FEEQ26746209-0C310A36-A67E-4D00-9C54-02604CB6603EQ26748775-6861F405-D284-43D3-885F-666A1302D684Q26750765-5030940A-7A52-49CE-948A-231D84E18E11Q26751268-3CEF4344-D37F-40CA-8F20-F8D5021EF231Q26751344-6FCB7C9B-2C90-4309-B18F-C0E435927514Q26753082-FBFB2A63-2A5E-4141-B869-0C8D118D9486Q26765438-B9E38970-DADF-4A67-BA95-E05302743E14Q26766066-82BEBFD3-DD3D-4322-BFF0-F6BD94DC2047Q26768558-726F5571-CD3B-4C1F-91B1-4CA06A68CF73Q26768641-2B04612E-4668-4369-95C7-3305AEAB400CQ26769713-67EDBFB1-1CDD-4119-8D95-9F6C4EAE275DQ26769963-D83CF563-A2B3-4209-9A9A-3B19D4FB1E8DQ26770780-75387215-AF4F-4AAB-ACA1-EFA2233F77C8Q26774641-F5078E55-9900-4613-9758-30076FDC9C83Q26775578-8F195642-67B6-46D4-864B-F6DACAC7EB37Q26775591-649A40AB-9682-4FB7-8E78-96BFEE4B3FDEQ26775769-ED03047F-24B7-4965-A0FE-2BDC0D7F4660Q26777557-2217A4D3-F343-410B-92F8-F321CB5FEA1DQ26778296-F5307A79-D325-45E9-BA76-45C18B439A85Q26778765-A38F0B91-B62E-4764-AF53-FBEBB5323CEAQ26778790-D561BB12-F02A-43E2-8623-BDA9B90DB659Q26795598-CEDDE596-9BD4-4268-8AD8-200A7A77F44FQ26796311-7F7C474E-1DCF-48E5-9DE7-FED6A8EEE194Q26797282-D8E8C33C-56A3-4689-811A-F1E5628BA7A1Q26797478-147DCBB1-8729-449B-8469-E205B202555FQ26798330-859DABBB-AF38-4FFB-8A21-0640B46BB07FQ26823789-13EDFE39-D8E8-4005-ADCD-406D08AFD497
P2860
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I study of single-agent ...... cs, and immunologic correlates
@ast
Phase I study of single-agent ...... cs, and immunologic correlates
@en
type
label
Phase I study of single-agent ...... cs, and immunologic correlates
@ast
Phase I study of single-agent ...... cs, and immunologic correlates
@en
prefLabel
Phase I study of single-agent ...... cs, and immunologic correlates
@ast
Phase I study of single-agent ...... cs, and immunologic correlates
@en
P2093
P2860
P3181
P356
P1476
Phase I study of single-agent ...... cs, and immunologic correlates
@en
P2093
Brahmer JR
McMiller TL
Pardoll DM
P2860
P304
P3181
P356
10.1200/JCO.2009.26.7609
P407
P577
2010-07-01T00:00:00Z